Leon Collis

Leon Collis has extensive work experience in the pharmaceutical and biotechnology industry. Leon is currently working as an Executive Director at Nimbus Therapeutics since July 2023. Prior to this, they held roles at Takeda as a Scientific Director from March 2021 to August 2023, and as an Associate Scientific Director from January 2018 to March 2021. Leon also worked at GSK as a Senior Scientific Investigator from June 2016 to January 2018.

Before that, they had a significant tenure at Pfizer, where they held various roles including Senior Principal Scientist in the Inflammation & Immunology Research Unit from November 2015 to June 2016, Principal Scientist in the Inflammation & Immunology Research Unit from September 2013 to November 2015, and Senior Scientist in the same unit from September 2009 to September 2013. At Pfizer, they had multiple responsibilities including project leadership, collaboration management, exploratory strategy development, and advisory board participation. Leon also mentored several Ph.D. students.

In the earlier part of their career, Leon worked as a Research Scientist at the Marine Biological Laboratory from September 2005 to August 2009, where they conducted studies on the bioenergetics of cardiac and neuronal cells. Leon made discoveries related to the metabolic phenotype associated with the overexpression of certain proteins and developed microelectrodes for measuring cell oxygen consumption.

Prior to that, they had a Postdoctoral Fellowship at NYU School of Medicine from November 2002 to June 2005, where they made significant contributions to the understanding of heart disease and trained clinical fellows on electrophysiology and imaging platforms.

Leon Collis obtained a Bachelor of Science (B.Sc.) degree in Biological Sciences from the University of Florida, where they studied from 1994 to 1995. Leon then continued their education at Lancaster University, where they earned a B.Sc. degree in Biological Sciences from 1993 to 1996. Leon Collis completed their formal education by pursuing a Ph.D. in Physiology/Pharmacology at the University of Rhode Island, which they attended from 1997 to 2002.